CL2-SN-38(DCA)

  Cat. No.:  DC39818   Featured
Chemical Structure
1036969-20-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 and a maleimidocaproyl linker. CL2-SN-38 has been linked to tumor-selective human monoclonal antibodies, such as anti-CEACAM5 (hMN-14) to target SN-38 to tumor sites and improve its solubility. CL2-SN-38 linked to hMN-14 binds (Kd = 1.4 nM) and is cytotoxic to LoVo human colon adenocarcinoma cells (IC50 = 5.3 nM). CL2-SN-38 linked to hMN-14 increases survival in a colon carcinoma mouse model of lung metastasis.
Cas No.: 1036969-20-6
Chemical Name: N-[32-[4-[[[[4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-1,5-dioxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azadotriacont-1-yl]-L-phenylalanyl-N-[4-[[[[[(4S)-4,11-diethyl-3,4,12,14-tetrahydro-9-hydrox
Synonyms: CL2-SN-38
SMILES: O=C1N(CC2=C3CC)C(C2=NC4=CC=C(O)C=C34)=CC([C@@](CC)5OC(OCC6=CC=C(NC([C@H](CCCCN)NC([C@@H](NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7C=C(CNC(C8CCC(CN(C9=O)C(C=C9)=O)CC8)=O)N=N7)=O)=O)CC%10=CC=CC=C%10)=O)=O)C=C6)=O)=C1COC5=O
Formula: C82H106N12O23
M.Wt: 1627.79
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: CL2-SN-38 is a part of the antibody drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. The anti-Trop-2 hRS7-CL2A-SN-38 ADC provides significant and specific antitumor effects against a range of human solid tumor types[1].
References: [1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC39818 CL2-SN-38(DCA) CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 and a maleimidocaproyl linker. CL2-SN-38 has been linked to tumor-selective human monoclonal antibodies, such as anti-CEACAM5 (hMN-14) to target SN-38 to tumor sites and improve its solubility. CL2-SN-38 linked to hMN-14 binds (Kd = 1.4 nM) and is cytotoxic to LoVo human colon adenocarcinoma cells (IC50 = 5.3 nM). CL2-SN-38 linked to hMN-14 increases survival in a colon carcinoma mouse model of lung metastasis.
DC50025 Deruxtecan Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate.
DC45695 Thailanstatin A Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC.
DC7648 PNU159682 PNU-159682 is a major bioactive metabolite of Nemorubicin in human liver microsomes; > 3,000-fold cytotoxic than its parent compound(MMDX and doxorubicin).
DC8241 Ansamitocin P-3 Ansamitocin P-3, a potent anti-tumor maytansinoid found in Actinosynnema pretiosum, is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29.
DC8540 DM-1(Mertansine) A cytotoxic agent used in antibody-drug conjugates
X